Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.

The Lancet. Oncology·2019
Same author

Radical trimodality therapy for patients with locally advanced bladder cancer: The British Columbia Cancer Agency experience.

Urologic oncology·2014
Same author

Is tremelimumab beneficial in advanced melanoma?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2013
Same author

Raltitrexed: optimism and reality.

Expert opinion on drug metabolism & toxicology·2009
Same author

Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience.

Cancer investigation·2007
Same author

Letter from Dr. Kenneth Wilson.

Current oncology (Toronto, Ont.)·2007

Related Experiment Video

Updated: Jun 12, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Adjuvant interferon alfa for melanoma

Kenneth S Wilson, Andrew Attwell

    Current Oncology (Toronto, Ont.)
    |June 23, 2010
    PubMed
    Summary

    No abstract available in PubMed .

    Keywords:
    Melanomaadjuvantinterferon

    More Related Videos

    Intralymphatic Immunotherapy and Vaccination in Mice
    07:33

    Intralymphatic Immunotherapy and Vaccination in Mice

    Published on: February 2, 2014

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
    07:41

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

    Published on: March 8, 2022

    Related Experiment Videos

    Last Updated: Jun 12, 2026

    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
    09:15

    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

    Published on: February 24, 2023

    Intralymphatic Immunotherapy and Vaccination in Mice
    07:33

    Intralymphatic Immunotherapy and Vaccination in Mice

    Published on: February 2, 2014

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
    07:41

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

    Published on: March 8, 2022